3
|
Toutouna L, Beck-Woedl S, Feige U, Glaeser B, Komlosi K, Eckenweiler M, Luetzen N, Haack TB, Fischer J, Bader I, Tzschach A. Novel homozygous LAMB1 in-frame deletion in a pediatric patient with brain anomalies and cerebrovascular event. Am J Med Genet A 2023; 191:2656-2663. [PMID: 37466007 DOI: 10.1002/ajmg.a.63349] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2023] [Revised: 06/07/2023] [Accepted: 06/28/2023] [Indexed: 07/20/2023]
Abstract
Biallelic pathogenic variants in LAMB1 have been associated with autosomal recessive lissencephaly 5 (OMIM 615191), which is characterized by brain malformations (cobblestone lissencephaly, hydrocephalus), developmental delay, and epilepsy. Pathogenic variants in LAMB1 are rare, with only 11 pathogenic variants and 11 patients reported to date. Here, we report on a 6-year-old patient from a consanguineous family with profound developmental delay, microcephaly, and a history of a perinatal cerebrovascular event. Brain magnetic resonance imaging (MRI) showed cerebellar cystic defects, signal intensity abnormalities, and a hypoplastic corpus callosum. Trio-exome analysis revealed a homozygous in-frame deletion of Exons 23 and 24 of LAMB1 affecting 104 amino acids including the epidermal growth factor (EGF)-like units 11 and 12 in Domain III. To our knowledge, this is the first reported in-frame deletion in LAMB1. Our findings broaden the clinical and molecular spectrum of LAMB1-associated syndromes.
Collapse
Affiliation(s)
- Louiza Toutouna
- Faculty of Medicine, Institute of Human Genetics, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany
| | - Stefanie Beck-Woedl
- Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany
| | - Ursula Feige
- Department of Neuroradiology, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany
| | - Birgitta Glaeser
- Faculty of Medicine, Institute of Human Genetics, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany
| | - Katalin Komlosi
- Faculty of Medicine, Institute of Human Genetics, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany
| | - Matthias Eckenweiler
- Department of Neuropediatrics and Muscle Disorders, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany
| | - Niklas Luetzen
- Department of Neuroradiology, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany
| | - Tobias B Haack
- Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany
| | - Judith Fischer
- Faculty of Medicine, Institute of Human Genetics, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany
| | - Ingrid Bader
- Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany
| | - Andreas Tzschach
- Faculty of Medicine, Institute of Human Genetics, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany
| |
Collapse
|
4
|
Morel H, Bailly L, Urbanczyk C, Hervé D, Berroir S, Le Bouc R, Levy R, Meyer M, Aloui C, Tournier-Lasserve E, Mathey G. Extension of the Clinicoradiologic Spectrum of Newly Described End-Truncating LAMB1 Variations. Neurol Genet 2023; 9:e200069. [PMID: 37063705 PMCID: PMC10096279 DOI: 10.1212/nxg.0000000000200069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2023] [Accepted: 02/14/2023] [Indexed: 04/18/2023]
Abstract
Objectives To refine the clinical spectrum of a very recently identified phenotype associated with LAMB1 end-truncating pathogenic variations. Methods Detailed clinical, neuropsychological, and MRI investigation of 6 patients from 2 unrelated families segregating end-truncating LAMB1 variations. Results All patients harbored a LAMB1 end-truncating pathogenic variation. The specific association of a hippocampal type episodic memory dysfunction and a diffuse leukoencephalopathy was observed in all 4 patients aged older than 50 years, slightly worsening over time in 2 patients with several years of follow-up. Additional unspecific neurologic symptoms are reported, such as episodes of numbness, language troubles, or faintness in these 4 patients and the 2 younger ones. Discussion The association of an extensive leukoencephalopathy with an episodic memory dysfunction of the hippocampal type is strongly suggestive of a LAMB1 end-truncating variation in adults older than 50 years. Early cognitive complaints and imaging abnormalities might exist decades before. Additional transient manifestations can be observed, and this association should lead to LAMB1 screening to avoid unnecessary invasive investigations.
Collapse
Affiliation(s)
- Hélène Morel
- Université de Paris (H.M., D.H., C.A., E.T.-L.), INSERM UMR 1141 NeuroDiderot; AP-HP (H.M., E.T.-L.), Service de Génétique Moléculaire Neurovasculaire, Hôpital Saint-Louis; Reference Centre for Rare or Early-Onset Dementias (L.B., R.L.B., R.L.), IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris; Centre Hospitalier Départemental La Roche-Sur-Yon (C.U.), Service de Neurologie, La Roche-Sur-Yon; AP-HP (D.H.), CERVCO, Centre de Neurologie Vasculaire Translationnelle, Hôpital Lariboisière; Service de Neurologie (S.B.), Centre Hospitalier Alpes Leman, Contamine sur Arve; and Service de Neurologie (M.M., G.M.), Centre Hospitalier Regional Universitaire de Nancy, France
| | - Laurent Bailly
- Université de Paris (H.M., D.H., C.A., E.T.-L.), INSERM UMR 1141 NeuroDiderot; AP-HP (H.M., E.T.-L.), Service de Génétique Moléculaire Neurovasculaire, Hôpital Saint-Louis; Reference Centre for Rare or Early-Onset Dementias (L.B., R.L.B., R.L.), IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris; Centre Hospitalier Départemental La Roche-Sur-Yon (C.U.), Service de Neurologie, La Roche-Sur-Yon; AP-HP (D.H.), CERVCO, Centre de Neurologie Vasculaire Translationnelle, Hôpital Lariboisière; Service de Neurologie (S.B.), Centre Hospitalier Alpes Leman, Contamine sur Arve; and Service de Neurologie (M.M., G.M.), Centre Hospitalier Regional Universitaire de Nancy, France
| | - Cédric Urbanczyk
- Université de Paris (H.M., D.H., C.A., E.T.-L.), INSERM UMR 1141 NeuroDiderot; AP-HP (H.M., E.T.-L.), Service de Génétique Moléculaire Neurovasculaire, Hôpital Saint-Louis; Reference Centre for Rare or Early-Onset Dementias (L.B., R.L.B., R.L.), IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris; Centre Hospitalier Départemental La Roche-Sur-Yon (C.U.), Service de Neurologie, La Roche-Sur-Yon; AP-HP (D.H.), CERVCO, Centre de Neurologie Vasculaire Translationnelle, Hôpital Lariboisière; Service de Neurologie (S.B.), Centre Hospitalier Alpes Leman, Contamine sur Arve; and Service de Neurologie (M.M., G.M.), Centre Hospitalier Regional Universitaire de Nancy, France
| | - Dominique Hervé
- Université de Paris (H.M., D.H., C.A., E.T.-L.), INSERM UMR 1141 NeuroDiderot; AP-HP (H.M., E.T.-L.), Service de Génétique Moléculaire Neurovasculaire, Hôpital Saint-Louis; Reference Centre for Rare or Early-Onset Dementias (L.B., R.L.B., R.L.), IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris; Centre Hospitalier Départemental La Roche-Sur-Yon (C.U.), Service de Neurologie, La Roche-Sur-Yon; AP-HP (D.H.), CERVCO, Centre de Neurologie Vasculaire Translationnelle, Hôpital Lariboisière; Service de Neurologie (S.B.), Centre Hospitalier Alpes Leman, Contamine sur Arve; and Service de Neurologie (M.M., G.M.), Centre Hospitalier Regional Universitaire de Nancy, France
| | - Stéphane Berroir
- Université de Paris (H.M., D.H., C.A., E.T.-L.), INSERM UMR 1141 NeuroDiderot; AP-HP (H.M., E.T.-L.), Service de Génétique Moléculaire Neurovasculaire, Hôpital Saint-Louis; Reference Centre for Rare or Early-Onset Dementias (L.B., R.L.B., R.L.), IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris; Centre Hospitalier Départemental La Roche-Sur-Yon (C.U.), Service de Neurologie, La Roche-Sur-Yon; AP-HP (D.H.), CERVCO, Centre de Neurologie Vasculaire Translationnelle, Hôpital Lariboisière; Service de Neurologie (S.B.), Centre Hospitalier Alpes Leman, Contamine sur Arve; and Service de Neurologie (M.M., G.M.), Centre Hospitalier Regional Universitaire de Nancy, France
| | - Raphaël Le Bouc
- Université de Paris (H.M., D.H., C.A., E.T.-L.), INSERM UMR 1141 NeuroDiderot; AP-HP (H.M., E.T.-L.), Service de Génétique Moléculaire Neurovasculaire, Hôpital Saint-Louis; Reference Centre for Rare or Early-Onset Dementias (L.B., R.L.B., R.L.), IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris; Centre Hospitalier Départemental La Roche-Sur-Yon (C.U.), Service de Neurologie, La Roche-Sur-Yon; AP-HP (D.H.), CERVCO, Centre de Neurologie Vasculaire Translationnelle, Hôpital Lariboisière; Service de Neurologie (S.B.), Centre Hospitalier Alpes Leman, Contamine sur Arve; and Service de Neurologie (M.M., G.M.), Centre Hospitalier Regional Universitaire de Nancy, France
| | - Richard Levy
- Université de Paris (H.M., D.H., C.A., E.T.-L.), INSERM UMR 1141 NeuroDiderot; AP-HP (H.M., E.T.-L.), Service de Génétique Moléculaire Neurovasculaire, Hôpital Saint-Louis; Reference Centre for Rare or Early-Onset Dementias (L.B., R.L.B., R.L.), IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris; Centre Hospitalier Départemental La Roche-Sur-Yon (C.U.), Service de Neurologie, La Roche-Sur-Yon; AP-HP (D.H.), CERVCO, Centre de Neurologie Vasculaire Translationnelle, Hôpital Lariboisière; Service de Neurologie (S.B.), Centre Hospitalier Alpes Leman, Contamine sur Arve; and Service de Neurologie (M.M., G.M.), Centre Hospitalier Regional Universitaire de Nancy, France
| | - Mylène Meyer
- Université de Paris (H.M., D.H., C.A., E.T.-L.), INSERM UMR 1141 NeuroDiderot; AP-HP (H.M., E.T.-L.), Service de Génétique Moléculaire Neurovasculaire, Hôpital Saint-Louis; Reference Centre for Rare or Early-Onset Dementias (L.B., R.L.B., R.L.), IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris; Centre Hospitalier Départemental La Roche-Sur-Yon (C.U.), Service de Neurologie, La Roche-Sur-Yon; AP-HP (D.H.), CERVCO, Centre de Neurologie Vasculaire Translationnelle, Hôpital Lariboisière; Service de Neurologie (S.B.), Centre Hospitalier Alpes Leman, Contamine sur Arve; and Service de Neurologie (M.M., G.M.), Centre Hospitalier Regional Universitaire de Nancy, France
| | - Chaker Aloui
- Université de Paris (H.M., D.H., C.A., E.T.-L.), INSERM UMR 1141 NeuroDiderot; AP-HP (H.M., E.T.-L.), Service de Génétique Moléculaire Neurovasculaire, Hôpital Saint-Louis; Reference Centre for Rare or Early-Onset Dementias (L.B., R.L.B., R.L.), IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris; Centre Hospitalier Départemental La Roche-Sur-Yon (C.U.), Service de Neurologie, La Roche-Sur-Yon; AP-HP (D.H.), CERVCO, Centre de Neurologie Vasculaire Translationnelle, Hôpital Lariboisière; Service de Neurologie (S.B.), Centre Hospitalier Alpes Leman, Contamine sur Arve; and Service de Neurologie (M.M., G.M.), Centre Hospitalier Regional Universitaire de Nancy, France
| | - Elisabeth Tournier-Lasserve
- Université de Paris (H.M., D.H., C.A., E.T.-L.), INSERM UMR 1141 NeuroDiderot; AP-HP (H.M., E.T.-L.), Service de Génétique Moléculaire Neurovasculaire, Hôpital Saint-Louis; Reference Centre for Rare or Early-Onset Dementias (L.B., R.L.B., R.L.), IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris; Centre Hospitalier Départemental La Roche-Sur-Yon (C.U.), Service de Neurologie, La Roche-Sur-Yon; AP-HP (D.H.), CERVCO, Centre de Neurologie Vasculaire Translationnelle, Hôpital Lariboisière; Service de Neurologie (S.B.), Centre Hospitalier Alpes Leman, Contamine sur Arve; and Service de Neurologie (M.M., G.M.), Centre Hospitalier Regional Universitaire de Nancy, France
| | - Guillaume Mathey
- Université de Paris (H.M., D.H., C.A., E.T.-L.), INSERM UMR 1141 NeuroDiderot; AP-HP (H.M., E.T.-L.), Service de Génétique Moléculaire Neurovasculaire, Hôpital Saint-Louis; Reference Centre for Rare or Early-Onset Dementias (L.B., R.L.B., R.L.), IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris; Centre Hospitalier Départemental La Roche-Sur-Yon (C.U.), Service de Neurologie, La Roche-Sur-Yon; AP-HP (D.H.), CERVCO, Centre de Neurologie Vasculaire Translationnelle, Hôpital Lariboisière; Service de Neurologie (S.B.), Centre Hospitalier Alpes Leman, Contamine sur Arve; and Service de Neurologie (M.M., G.M.), Centre Hospitalier Regional Universitaire de Nancy, France
| |
Collapse
|
5
|
Uemura M, Hatano Y, Nozaki H, Ando S, Kondo H, Hanazono A, Iwanaga A, Murota H, Osakada Y, Osaki M, Kanazawa M, Kanai M, Shibata Y, Saika R, Miyatake T, Aizawa H, Ikeuchi T, Tomimoto H, Mizuta I, Mizuno T, Ishihara T, Onodera O. High frequency of HTRA1 AND ABCC6 mutations in Japanese patients with adult-onset cerebral small vessel disease. J Neurol Neurosurg Psychiatry 2023; 94:74-81. [PMID: 36261288 PMCID: PMC9763231 DOI: 10.1136/jnnp-2022-329917] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/04/2022] [Accepted: 09/29/2022] [Indexed: 11/05/2022]
Abstract
BACKGROUND This study aimed to clarify the frequency and clinical features of monogenic cerebral small vessel disease (mgCSVD) among patients with adult-onset severe CSVD in Japan. METHODS This study included patients with adult-onset severe CSVD with an age of onset ≤55 years (group 1) or >55 years and with a positive family history (group 2). After conducting conventional genetic tests for NOTCH3 and HTRA1, whole-exome sequencing was performed on undiagnosed patients. Patients were divided into two groups according to the results of the genetic tests: monogenic and undetermined. The clinical and imaging features were compared between the two groups. RESULTS Group 1 and group 2 included 75 and 31 patients, respectively. In total, 30 patients had NOTCH3 mutations, 11 patients had HTRA1 mutations, 6 patients had ABCC6 mutations, 1 patient had a TREX1 mutation, 1 patient had a COL4A1 mutation and 1 patient had a COL4A2 mutation. The total frequency of mutations in NOTCH3, HTRA1 and ABCC6 was 94.0% in patients with mgCSVD. In group 1, the frequency of a family history of first relatives, hypertension and multiple lacunar infarctions (LIs) differed significantly between the two groups (monogenic vs undetermined; family history of first relatives, 61.0% vs 25.0%, p=0.0015; hypertension, 34.1% vs 63.9%, p=0.0092; multiple LIs, 87.8% vs 63.9%, p=0.0134). CONCLUSIONS More than 90% of mgCSVDs were diagnosed by screening for NOTCH3, HTRA1 and ABCC6. The target sequences for these three genes may efficiently diagnose mgCSVD in Japanese patients.
Collapse
Affiliation(s)
- Masahiro Uemura
- Department of Neurology, Clinical Neuroscience Branch, Brain Research Institute, Niigata University, Niigata, Japan
| | - Yuya Hatano
- Department of Neurology, Clinical Neuroscience Branch, Brain Research Institute, Niigata University, Niigata, Japan
| | - Hiroaki Nozaki
- Department of Medical Technology, Graduate School of Health Sciences, Niigata University, Niigata, Japan
| | - Shoichiro Ando
- Department of Neurology, Clinical Neuroscience Branch, Brain Research Institute, Niigata University, Niigata, Japan
| | - Hajime Kondo
- Department of Neurology, Anjo Kosei Hospital, Aichi, Japan
| | - Akira Hanazono
- Division of Gastroenterology, Hepato-biliary-pancreatology and Neurology, Akita University, Akita, Japan
| | - Akira Iwanaga
- Department of Dermatology, Nagasaki University, Nagasaki, Japan
| | - Hiroyuki Murota
- Department of Dermatology, Nagasaki University, Nagasaki, Japan
| | - Yosuke Osakada
- Department of Neurology, Okayama University, Okayama, Japan
| | - Masato Osaki
- Cerebrovascular Medicine, Steel Memorial Yawata Hospital, Fukuoka, Japan
| | - Masato Kanazawa
- Department of Neurology, Clinical Neuroscience Branch, Brain Research Institute, Niigata University, Niigata, Japan
| | - Mitsuyasu Kanai
- Department of Neurology, National Hospital Organization Takasaki General Medical Center, Gunma, Japan
| | - Yoko Shibata
- Department of Neurology, Japanese Red Cross Osaka Hospital, Osaka, Japan
| | - Reiko Saika
- Department of Neurology, Japanese Red Cross Osaka Hospital, Osaka, Japan
| | | | - Hitoshi Aizawa
- Department of Neurology, Tokyo Medical University, Tokyo, Japan.,Department of Neurology, Tokyo National Hospital, Tokyo, Japan
| | - Takeshi Ikeuchi
- Department of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Japan
| | | | - Ikuko Mizuta
- Department of Neurology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - Toshiki Mizuno
- Department of Neurology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - Tomohiko Ishihara
- Department of Neurology, Clinical Neuroscience Branch, Brain Research Institute, Niigata University, Niigata, Japan
| | - Osamu Onodera
- Department of Neurology, Clinical Neuroscience Branch, Brain Research Institute, Niigata University, Niigata, Japan
| |
Collapse
|